The implications of chemotherapeutic drug-drug interactions can be serious and thus need to be addressed. This review concerns the potential interactions of the antiemetic aprepitant, a neurokinin-1 receptor antagonist indicated for use (in Europe) in highly emetogenic chemotherapy and moderately emetogenic chemotherapy (MEC) in combination with a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and corticosteroids and (in the United States) in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. When considering use of aprepitant for prevention of chemotherapy-induced nausea and vomiting, its potential drug-drug interaction profile as a moderate inhibitor of cytochrome P-450 isoenzyme 3A4 (CYP3A4) has been a source of concern for some physicians and other health care professionals. We explore in this paper how real those concerns are. Our conclusion is that either no interaction or no clinically relevant interaction exists with chemotherapeutic agents (intravenous cyclophosphamide, docetaxel, intravenous vinorelbine) or 5-HT3 antagonists (granisetron, ondansetron, palonosetron). For relevant interactions, appropriate measures, such as corticosteroid dose modifications and extended International Normalized Ratio monitoring of patients on warfarin therapy, can be taken to effectively manage them. Therefore, the concern of negative interactions remains largely theoretical but needs to be verified with new agents extensively metabolized through the 3A4 pathway.
introduction
While drug-drug interactions are a valid concern in all patients, it should be recognized that not all potential drug interactions have clinical consequences and many are manageable [1] . The use of multiple drugs at once is a common feature of care for cancer patients; not only are these patients likely taking more than one chemotherapeutic agent but they are also in need of supportive care and thus rely on several other drugs for analgesia, anemia, neutropenia, depression, etc, as well as prevention of nausea and vomiting which may involve a threedrug combination that may include a 5-HT3 (serotonin-3) receptor antagonist, a corticosteroid, and an neurokinin (NK)-1 receptor antagonist, presently aprepitant. The various metabolic pathways involved in drug metabolism account for many important drug interactions and therefore, it is important to consider both the number of drugs that patients take as well as the specific metabolic pathways of each.
The cytochrome P-450 isoenzyme 3A4 (CYP3A4) is a major metabolic pathway for drugs in the human body including many of the drugs used by patients to treat the symptoms caused by cancer and its treatment as well as their other illnesses including cardiovascular disease. CYP3A4 can be both inhibited and induced by drugs, leading to many complex and important drug interactions. Potent inhibitors of CYP3A4 have the potential to interact with cytotoxic agents to cause adverse effects. It is essential to understand the clinical impact of drugdrug interactions affecting chemotherapy treatment to provide patients with the best possible care.
the need for aprepitant Nausea and vomiting are frequently cited as the most distressing side-effects of chemotherapy [2, 3] . Up to 75% of all cancer patients will experience chemotherapy-related emesis with increased risk associated with specific chemotherapeutic agents used, female gender, age <50 years, and history of nausea or vomiting (including during pregnancy, prior chemotherapy use, motion sickness) [4, 5] . The introduction of antiemetic therapy with a corticosteroid and a 5-HT3 receptor antagonist significantly improved the control rate of chemotherapyinduced nausea and vomiting (CINV) in the 1990s. Two important neuropeptide receptors involved in the mechanism of emesis following chemotherapy treatment have been identified. Serotonin receptors in the gastrointestinal (GI) tract and in the central nervous system are important in the early development of emesis; 5-HT3 receptor antagonists in particular have been shown to provide relief from emesis in experimental animals and patients that have been treated with cytotoxic drugs [6, 7] . Chemotherapy agents stimulate release of serotonin from the GI tract as well as substance P, a neuropeptide from the tachykinin family, from sensory neurons [8] . Substance P also has a role in the emetic reflex; it binds NK receptors that are located in the periphery and in the brain stem. Central NK-1 receptors are considered to be most relevant in the emetic pathway [9, 10] . In the first 8 h (acute phase), postchemotherapy emesis is particularly responsive to 5-HT3 receptor antagonists indicating that peripheral serotonin interaction with 5-HT3 receptors is predominantly responsible [11] . The delayed phase of CINV is defined as emesis which occurs beyond 24 h after chemotherapy (typically with cisplatin, cyclophosphamide, carboplatin, and anthracyclines) and successful management of this phase rarely exceeded 50% [12] [13] [14] [15] . While dexamethasone is considered an important agent in controlling emesis in this delayed phase [14] , much needed improvement of CINV management came with the introduction of the NK-1 receptor antagonists, a new class of antiemetics, as well as of palonosetron, a long-acting 5-HT3 receptor antagonist [16] .
Aprepitant is an NK-1 receptor antagonist that crosses the blood-brain barrier to exert its antiemetic effect [10] and has been approved for the prevention of CINV in patients receiving highly emetogenic chemotherapy and MEC. Aprepitant has been initially evaluated in four phase III double-blind randomized studies, three of which involved high-dose cisplatin and one with chemotherapy containing an anthracycline plus cyclophosphamide for breast cancer [13, [17] [18] [19] . The standard therapy arms contained ondansetron and dexamethasone; in the experimental arm, aprepitant in the currently approved dose and schedule was added to ondansetron and dexamethasone. The addition of aprepitant resulted in an absolute difference in complete response (CR; absence of retching or vomiting and no use of an 'as-needed' antiemetic) of 14%-21% in the cisplatin trials and a difference of 9% with MEC. The lesser difference with MEC was attributed to a lack of effect on nausea with aprepitant; however, for retching or vomiting alone, a similar difference with aprepitant among all phase III studies was demonstrated with a 17% difference achieved with MEC and a 14.3%-22.7% difference with cisplatin. Furthermore, significant improvement with aprepitant was observable in both the acute (first 24 h) and delayed (24-120 h) CINV phases. Aprepitant had an overall positive tolerability profile in these studies with the most common adverse events being fatigue, anorexia, dyspepsia, constipation, diarrhea and hiccups [13, 17, 18] . Adverse events seen in the aprepitant-containing arms of phase III clinical trials were similar to those seen with standard therapy even though patients commonly received concomitant taxanes and vinca alkaloids [19, 20] .
A time course of the antiemetic effect of aprepitant demonstrating longer-lasting emetic control in the delayed CINV phase compared with prevention without aprepitant strongly indicates a key role for a NK-mediated mechanism in CINV [21] . The delayed phase of CINV was poorly controlled, underestimated in its importance and incidence by physicians and nurses [22, 23] . For example, the use of a 5-HT3 antagonist plus dexamethasone 1 day before oxaliplatin administration in colon cancer patients resulted in sufficient control of acute emesis (CR 91%) but was only about half as effective (CR 49%) during the delayed phase [4] . Similarly, newly diagnosed lung patients who received one cycle of carboplatin-based therapy without prophylactic aprepitant administration experienced moderate to severe CINV as long as 72 (36%) and 96 (33%) h [24] .
While the addition of aprepitant to combination antiemetic therapy has greatly improved the management of CINV, both in the acute and delayed phases of emesis, as discussed later in this paper, caution may still prevail among physicians when considering the use of aprepitant for the prevention of CINV due to its potential drug-drug interaction profile as a moderate inhibitor of CYP3A4. The question persists as to how real those concerns are, and this paper explores the various studies that answer this question.
pharmacokinetics than pharmacology of aprepitant
Aprepitant is used in combination with corticosteroids and 5-HT3 receptor antagonists to prevent CINV associated with highly emetogenic chemotherapy and MEC. Aprepitant improves acute and delayed phase control of vomiting and maintains its efficacy over multiple cycles of chemotherapy [13, 17, 25] . Aprepitant is an oral formulation with $65% bioavailability; it also has a prodrug, fosaprepitant, which is available as an i.v. preparation. Following oral administration, peak plasma concentrations are achieved in 4 h, and its absorption is not affected by food. Aprepitant is recommended for once-a-day (QD) administration as it has a terminal half-life of 9-13 h. It is indicated for use for a maximum of three consecutive days per chemotherapy cycle at a recommended oral dose of 125 mg on day 1 of treatment 1 h before chemotherapy and 80 mg QD on days 2 and 3. Mild hepatic or renal insufficiency does not affect dosage and adjustments are not required on the basis of age, race, or gender. On the basis of publicly available data, oral aprepitant (125 mg) and i.v. fosaprepitant (115 mg) have similar mean plasma concentrations at 24 h after dose and fosaprepitant up to 150 mg is generally well tolerated [26] . The primary pathway of aprepitant elimination is the CYP3A4 [27] . CYP3A is the most abundant isoenzyme expressed in the human liver and small intestine and is involved in the metabolism of various anticancer drugs [28] . In addition to being a substrate, aprepitant has been shown to moderately inhibit CYP3A4 and mildly induce CYP2C9 [29, 30] . These findings indicate that possible drug-drug interactions may occur when aprepitant is coadministered with drugs, including anticancer agents, metabolized by either of these enzymes. However, it has been noted through a number of pharmacokinetic studies that the impact of most of these interactions is not clinically significant and leads to dose adjustments in few circumstances (Table 1) .
aprepitant drug interactions put into perspective considering that aprepitant is known to modify key isoenzymes and is coadministered with several medications that are substrates of those enzymes. Indeed, the required dose reduction of dexamethasone when given with aprepitant indicates a clinically relevant potential for significant interactions. Thus, the assumption has been that there is a potential risk of drug-drug interactions with its use. However, not only is it important to determine which aprepitant interactions are clinically relevant but it is also necessary to put those interactions into clinical perspective with other drugs that are isoenzyme modifiers. The effect of aprepitant on CYP3A4 and CYP2C9 has been studied using established probes to each of these enzymes [29, 30] . Interactions with aprepitant appear to be more pronounced with oral drugs compared with i.v. drugs, and hence CYP3A4 in the gut may be more important for drug interactions. Midazolam is a benzodiazepine that undergoes extensive first-pass metabolism by both hepatic and intestinal CYP3A4. Midazolam given i.v. is an established probe to measure CYP3A4 in the liver, whereas midazolam given orally is useful for CYP3A4 measurement in the gut and liver. The pharmacokinetics of midazolam has been correlated with the activity of CYP3A4 and can be used to detect changes in the activity of the enzyme. This is helpful for determining the extent to which a drug of interest affects CYP3A4. This information can be used to classify the drug of interest as a CYP3A4 inhibitor or inducer in vivo [50] . Findings that a 5-day regimen of aprepitant coadministration with oral midazolam in healthy male subjects resulted in a significant increase (3.3-fold; P < 0.01) in area under the concentrationtime curve (AUC) plasma concentration and maximum observed concentration (1.9-fold; P < 0.01) of midazolam confirmed aprepitant as an inhibitor of CYP3A4 [29] . An additional study reported a 25% increase (versus placebo) of i.v. midazolam AUC [30] . However, a 25% increase is of marginal clinical significance in comparison with other drugs that modify CYP3A4 to a much greater degree. For example, a strong metabolic inducer like rifampin caused a 96% reduction in midazolam AUC [51] and both ketoconazole and itraconazole increased the midazolam AUC 10-15 times (P < 0.001) and the mean peak concentrations three to four times (P < 0.001) [52] . Therefore, on the basis of the midazolam classification scale, aprepitant inhibition of CYP3A4 is considered moderate and is comparable with inhibition by two calcium channel blockers, diltiazem and verapamil [50] .
Few, if any, chemotherapeutic agents are metabolized by CYP2C9 and therefore, the inductive effect of aprepitant on this enzyme could be considered less important. However, some of the additional drugs used for comorbid conditions or supportive care may be metabolized by CYP2C9. Oral tolbutamide was used as a CYP2C9 probe drug to examine the effect of aprepitant on this enzyme in healthy subjects [30] . Aprepitant had a small but statistically significant effect on the pharmacokinetics of tolbutamide but was not considered clinically relevant as this effect was weak and transient. For agents that have a small therapeutic index, like warfarin, this interaction needs to be considered [53] . However, for most other drugs metabolized by CYP2C9, such as some nonsteroidal anti-inflammatory drugs (e.g. diclofenac), a slight decrease in plasma concentration is unlikely to be of clinical importance.
aprepitant impact on chemotherapeutic agents
Anticancer drugs known to be metabolized by CYP3A4 include vinca alkaloids (vincristine, vinblastine, and vinorelbine), docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, gefitinib, and dasatinib. Cyclophosphamide autoinduces its own metabolism through several isoenzyme pathways, and CYP3A4 does not play a major role in its metabolism to the 4-OH active metabolite. The concern is for inducing elevated plasma concentrations of such chemotherapeutic drugs through interactions with CYP3A4 modifiers, resulting in increased toxic effects. Clinical trials of aprepitant with anticancer drugs, including cyclophosphamide, etoposide, taxanes, and vinca alkaloids, failed to produce any clinically significant interaction; however, pharmacokinetic analysis was not always evaluated in the clinical studies [54] .
Vinorelbine is a vinca alkaloid that is regularly administered with cisplatin [55] and is particularly sensitive to changes in CYP3A4 activity and thereby drugs that are able to inhibit or induce CYP3A4 activity [56] . Coadministration of aprepitant with vinorelbine could potentially decrease its metabolism, thereby increasing exposure to the active agent and toxicity. Yet a pharmacokinetic drug interaction study investigating potential interactions found that aprepitant had no clinically significant effect on i.v. vinorelbine pharmacokinetics; the geometric mean vinorelbine plasma AUC ratio was the same on day 1 [1.01; 90% confidence interval (CI) 0.93-1.10] as on day 8 (1.00; 90% CI 0.92-1.08), indicating no clinically relevant inhibiting or inductive effect of the 3-day aprepitant regimen combined with dexamethasone and ondansetron [34] . Docetaxel is primarily metabolized by CYP3A4 and patients with the lowest CYP3A4 activity experience lower clearance of the drug and consequently greater toxicity, manifested as longer and/or more severe neutropenia and other adverse events [33] . Coadministration of docetaxel with drugs that induce, inhibit, or are metabolized by CYP3A4 is only recommended with caution. Aprepitant has not been shown to cause any clinically significant alterations in pharmacokinetics of docetaxel or of its toxicity (adverse events and neutropenia) compared with administration of docetaxel alone in cancer patients [33] . The geometric mean AUC ratio of docetaxel plus aprepitant (3.17 mgÁh/ml) versus docetaxel alone (3.26 mgÁh/ml) was 0.97 (90% CI 0.86-1.10). Furthermore, even as 95% of patients in the phase III studies received other concomitant chemotherapeutic agents that are CYP3A4 substrates, such as etoposide and paclitaxel, doses were not adjusted to account for potential drug interactions [13, 17, 18] . These findings indicate that although aprepitant is a moderate inhibitor of CYP3A4, it does not necessarily significantly increase the plasma levels or otherwise alter the pharmacokinetics of other i.v. chemotherapeutic agents that are also CYP3A4 substrates.
Cyclophosphamide is a prodrug that is metabolized to its active metabolite of 4-OH-cyclophosphamide primarily via CYP2B6 and is metabolized to toxic and inactive metabolites via CYP3A4 [57] ; its efficacy is therefore unlikely to be altered through inhibition of CYP3A4. The results of cyclophosphamide studies support the use of aprepitant as part of prophylactic antiemetic therapy in patients receiving an MEC regimen of AC [31] . The effect of aprepitant on the pharmacokinetics of these agents was not directly studied in the phase III trial; however, adverse events were similar in treatment groups with or without aprepitant [19] . In another study, aprepitant was shown to significantly improve CINV in patients taking high-dose cyclophosphamide (1500 mg/m 2 /day · 4 days) for stem-cell transplant (0.5 vomiting days versus 4.8 days without aprepitant; P < 0.001) [31] . Early results of aprepitant use with standard antiemetics during high-dose cyclophosphamide-based conditioning do not show changes in cyclophosphamide pharmacokinetics or increased toxicity [58] . This is reassuring also in view that the typical dose of cyclophosphamide used in many i.v. regimens for breast cancer and lymphoma is much lower (600 mg/m 2 ). The influence of aprepitant on the pharmacokinetics of cyclophosphamide in this study was analyzed using a population pharmacokinetic analysis including a reference population of 49 patients receiving the same chemotherapy regimen without aprepitant and sampled under the same conditions. The rates of cyclophosphamide autoinduction and thiotepa clearance were significantly reduced by 23% (P = 0.04) and 33% (P < 0.001), respectively. There was large interindividual (45.8% thiotepa; 54.0% cyclophosphamide) and intraindividual variability in clearance of these drugs; however, the effect of aprepitant was considered small and of minor clinical importance [31] . The effect of aprepitant on the pharmacokinetics of cyclophosphamide as part of the breast cancer regimen called AC (doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 ) is currently being investigated by Walko et al. in a randomized, double-blind, two-period crossover study. Patients received cyclophosphamide plus aprepitant (125 mg on day 1 and 80 mg on days 2 and 3) or placebo in the two periods. Seventeen patients have completed two cycles. There was no statistically significant change in the AUC of the active metabolite of cyclophosphamide (4-OH metabolite) when cyclophosphamide was given with aprepitant [32] .
Ifosfamide is another prodrug that requires activation by CYP3A4 enzyme. Metabolism results in both the active metabolite (4-hydroxy-ifosfamide [4OH-Ifo]) as well as inactive but neurotoxic metabolites (2-and 3-dechloroethylifosfamide [2d-Ifo and 3d-Ifo]) [35] . A report of an individual developing acute encephalopathy following ifosfamide infusion and aprepitant administration [35] and a retrospective observation of a series of patients receiving ifosfamide [36] indicate a possible interaction which can lead to an increased risk of encephalopathy. These data should prompt a prospective pharmacokinetic evaluation. It should be noted that encephalopathy is a rare but well-known adverse reaction to ifosfamide [59] .
The importance of understanding potential drug-drug interactions between antiemetics and cytotoxins cannot be overstated. At present, there is no evidence that such interactions with aprepitant are of major clinical importance. Scope remains to understand the consequences of drug-drug interactions in patients taking multiday chemotherapy, in new combinations of cytotoxics and targeted agents for cancer therapy.
management of aprepitant effect on corticosteroids
Both dexamethasone and methylprednisolone are metabolized by CYP3A4 [39, 40, 60] and the impact of aprepitant on the pharmacokinetics of these drugs is clinically relevant. In a phase IIB study, the addition of aprepitant to the standard oral dexamethasone (20 mg dexamethasone on day 1, 8 mg dexamethasone on days 2-5) plus ondansetron (32 mg i.v. on day 1 only) regimen resulted in a 2.2-fold increase in the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ). The results were similar when a modified regimen of oral dexamethasone was used (12 mg on day 1, followed by 4 mg on days 2-5). Methylprednisolone is also used for CINV management and its metabolism is sensitive to aprepitant. Aprepitant increased the AUC 0-24 of i.v. methylprednisolone 1.3-fold on day 1 (P < 0.010) and of oral methylprednisolone 2.5-fold on day 3 (P < 0.010) [37] . Therefore, it is recommended to dose-reduce i.v. and oral methylprednisolone by 25% and 50%, respectively, when coadministered with aprepitant.
Exposure to high doses of corticosteroids has not been studied for its antiemetic properties [14] . Usage of steroids, such as dexamethasone, at higher doses may be associated with a higher incidence of febrile neutropenia and serious infections compared with standard therapy [38] . Accordingly, in the subsequent phase III trials, the oral dexamethasone dose when coadministered with aprepitant was reduced by 50% to achieve exposures similar to those obtained without aprepitant and is the current dosage adjustment recommended by the aprepitant prescribing information. It is worth noting that there were no further reports of febrile neutropenia following the dose reduction of dexamethasone in the phase III studies.
Recent data indicate that while oral dexamethasone should be decreased by 50%, this might be not necessary for i.v. dexamethasone since there is less CYP3A4 gut effect involved [61] . Thus, the pharmacokinetic impact of aprepitant on corticosteroids used in the antiemetic regimens can be easily managed using dose adjustments.
lack of clinical effect by aprepitant on 5-HT3 antagonists
Ondansetron and granisetron are two commonly used firstgeneration 5-HT3 receptor antagonists in the prevention of CINV and both are metabolized by the CYP system. Ondansetron is metabolized by numerous CYP enzymes, including CYP1A2, CYP2D6, and CYP3A4 [62] , while granisetron appears to be metabolized by the CYP3A family [41] . Although there are very few clinically relevant interactions listed for ondansetron, it has been shown to have interactions at supratherapeutic doses with a number of agents, including cyclophosphamide, antidepressants, and analgesics [43] [44] [45] [46] . In healthy subjects, a supratherapeutic dose (three times the recommended dose) of aprepitant caused a small but review Annals of Oncology statistically significant increase in ondansetron plasma concentration (from 1268.3 to 1456.5 ngÁh/ml; P = 0.019). No effect was found on the t 1/2 or C max of ondansetron in the presence of high-dose aprepitant [42] . On the basis of the lack of a clinically important interaction, it is assumed that the therapeutic dose of aprepitant would have little effect on oral ondansetron. The therapeutic dose of aprepitant had no effect on mean pharmacokinetic parameters of oral granisetron [42] . Hydrodolasetron is an active metabolite of dolasetron which is primarily metabolized through the CYP2D6 pathway and may alternatively use the CYP3A4 pathway in poor CYP2D6 metabolizers. However, a lack of effect by aprepitant on hydrodolasetron pharmacokinetics was found in healthy volunteers irrespective of metabolizer type [63] .
Palonosetron is a second-generation 5-HT3 receptor antagonist with a prolonged duration of action and higher receptor-binding affinity than first-generation antagonists like ondansetron and granisetron [16, 64] . It has also been studied in combination with dexamethasone and aprepitant [65] . In vitro, palonosetron has been shown to be primarily metabolized by CYP2D6 and, to a lesser extent, by CYP1A2 and CYP3A with both renal and hepatic clearance being equally important to its elimination [66] . In clinical pharmacokinetic interaction studies, aprepitant was found to have no effect on the pharmacokinetics of palonosetron and thus, palonosetron did not require a dose adjustment when coadministered with aprepitant [47] .
other aprepitant interactions to consider warfarin Warfarin is an oral coumarin-based anticoagulant prescribed for the treatment and prophylaxis of various thromboembolic diseases such as deep venous thrombosis and pulmonary embolism [67] . Warfarin is frequently prescribed for cancer patients for the prevention of venous access thrombosis as well as the treatment of hypercoagulation conditions. It is a rac mixture of its R-and S-enantiomers, but most of the pharmacological activity resides with the S-enantiomer [68] . Warfarin enantiomers are extensively metabolized in the liver by different CYP enzymes: CYP3A4 and CYP1A2 primarily metabolize the R-enantiomer, whereas the S-enantiomer is mainly metabolized by CYP2C9 [69] . Drug interactions with this anticoagulant are important as enhanced exposure may be associated with an increased risk of hemorrhage and reduced exposure can diminish its anticoagulant effect.
Several drugs, including prescription, over-the-counter, and herbal medicines, are known to have significant interactions with warfarin, requiring their discontinuation or dose adjustments [70] . As cancer patients could likely require warfarin and aprepitant concomitantly and aprepitant is a mild inducer of CYP2C9, its effect on warfarin pharmacokinetics and pharmacodynamics was investigated in healthy patients stabilized on chronic warfarin therapy [49] . Aprepitant was administered at its recommended 3-day regimen and on day 3, no significant effect on the plasma AUC of R-or S-enantiomers was found. Five days after the completion of aprepitant dosing, a significant reduction (34%) in the plasma S-enantiomer concentration in conjunction with a 14% decrease in prothrombin time [reported as International Normalized Ratio (INR)] was demonstrated. The S-enantiomer is primarily responsible for the anticoagulant effect of warfarin and these results are consistent with aprepitant induction of CYP2C9. Consequently, it is recommended that in patients on chronic warfarin therapy, the INR be closely monitored for the 2-week period following the 3-day regimen, particularly for 7-10 days. It should be noted that once-monthly monitoring is indicated as standard protocol in all patients with stable INR on warfarin therapy [71] and guidelines are available to help physicians adjust warfarin dosages if needed [72] as an extensive list of drugs, herbal products and food are known to interact with warfarin.
oral contraceptives
Contraception is recommended during, and for 1 month following, aprepitant treatment. It was noted that when given QD 100 mg for 14 days, with an oral contraceptive containing 35 lg of ethinyl estradiol and 1 mg of norethindrone, aprepitant decreased the AUC of ethinyl estradiol and norethindrone by 43% and 8%, respectively. In combination with ondansetron and dexamethasone, a 3-day regimen of aprepitant given during days 8-10 of a 21-day oral contraceptive cycle decreased trough concentrations of ethinyl estradiol and norethindrone by $60% during days 9 through 21 [48] . Using alternate methods of contraception during aprepitant treatment is appropriate. Moreover, secondary barrier contraceptive methods should be used with any chemotherapy regimens as most chemotherapeutic agents are known teratogenics.
conclusions
The addition of aprepitant to standard therapy has improved emesis in both the acute and delayed phases of CINV, thereby addressing this unmet need in CINV patients as chemotherapy compliance and quality of life are enhanced with its use. Accordingly, major antiemesis guidelines, such as the European Society for Medical Oncology, the Multinational Association for Supportive Care in Cancer and the American Society of Clinical Oncology, now recommend aprepitant as part of standard antiemetic therapy in high-risk patients (a category which comprises cisplatin-based regimens and female patients treated with anthracycline-cyclophosphamide-based combinations) [73] [74] [75] . It has been shown that patients on high-dose chemotherapy regimens who experienced substantial nausea and vomiting were not treated according to any guideline [76] , indicating that incomplete CINV management is not necessarily due to the lack of efficacious treatments but rather the lack of drug use by health care providers.
Any apprehension about using aprepitant for combination CINV management should be eased with the knowledge that most drug-drug interactions with aprepitant have little or no clinical consequence (Table 1) . Dose adjustments required with dexamethasone and methylprednisolone use have been proven to appropriately modify drug exposures and not result in further drug toxicity. It is important that these drug interactions be put into perspective to help clarify the usefulness of and need for aprepitant in patients at high or moderate risk from CINV. references
